Co-crystal of tramadol-celecoxib (CTC) for acute moderate-to-severe pain

CONCLUSIONS: Results from phase 3 trials suggest that the modified physicochemical properties of tramadol and celecoxib in CTC translate into an improved clinical benefit-risk profile, including fewer opioid-related adverse effects due to lower overall opioid dosing.PMID:38205948 | DOI:10.1080/03007995.2023.2276118

Source: Current Medical Research and Opinion - January 11, 2024 Category: Research Authors: Richard Langford Cesar Margarit Adelaida Morte Jes ús Cebrecos Mariano Sust Esther Ortiz Jos é María Giménez-Arnau Oscar de Leon-Casasola Source Type: research